Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up

Journal of Clinical Oncology

Volumn 30, Issue 25, 2012, Pages 3044-3050

  Castle, Philip E ^a   Glass, Andrew G ^b   Rush, Brenda B ^b   Scott, David R ^b   Wentzensen, Nicolas ^c   Gage, Julia C ^c   Buckland, Julie ^d   Rydzak, Greg ^d   Lorincz, Attila T ^e   Wacholder, Sholom ^c  

^a American Society for Clinical Pathology   (United States)

^b CENTER FOR HEALTH RESEARCH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE; CANCER INCIDENCE; CANCER RISK; CERVICOVAGINAL LAVAGE; CONTROLLED STUDY; DISEASE SEVERITY; DNA DETERMINATION; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRECANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UTERINE CERVIX CANCER; VAGINAL LAVAGE; VERRUCA VULGARIS; VIRUS DETECTION; WART VIRUS;

ADULT; AGE FACTORS; AGED; ALGORITHMS; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEALTH MAINTENANCE ORGANIZATIONS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MASS SCREENING; MIDDLE AGED; OREGON; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THERAPEUTIC IRRIGATION; TIME FACTORS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84865772757     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.8389     Document Type: Article

References (42)

1. Kjaer SK, Sigurdsson K, Iversen OE, et al: A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila Pa) 2:868-878, 2009
2. Paavonen J, Naud P, Salmerón J, et al: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and pre-cancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 374:301-314, 2009
3. Mayrand MH, Duarte-Franco E, Rodrigues I, et al: Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357:1579-1588, 2007
4. Bulkmans NW, Berkhof J, Rozendaal L, et al: Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370:1764-1772, 2007
5. Naucler P, Ryd W, Törnberg S, et al: Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 357:1589-1597, 2007
6. Ronco G, Giorgi-Rossi P, Carozzi F, et al: Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: A randomised controlled trial. Lancet Oncol 11:249-257, 2010
7. Anttila A, Kotaniemi-Talonen L, Leinonen M, et al: Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: Randomised study within organised screening programme. BMJ 340:c1804, 2010
8. Saslow D, Solomon D, Lawson HW, et al: American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 62:147-172, 2012
9. Saslow D, Solomon D, Lawson HW, et al: American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis [epub ahead of print on March 13, 2012]
10. Moyer VA: Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med [epub ahead of print on March 14, 2012]
11. Khan MJ, Castle PE, Lorincz AT, et al: The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97:1072-1079, 2005
12. Schiffman M, Glass AG, Wentzensen N, et al: A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev 20:1398-1409, 2011
13. Castle PE, Stoler MH, Wright TC Jr, et al: Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: A subanalysis of the ATHENA study. Lancet Oncol 12:880-890, 2011
14. Sherman ME, Lorincz AT, Scott DR, et al: Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: A 10-year cohort analysis. J Natl Cancer Inst 95:46-52, 2003
15. Schiffman MH, Bauer HM, Hoover RN, et al: Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 85:958-964, 1993
16. Arbyn M, Bergeron C, Klinkhamer P, et al: Liquid compared with conventional cervical cytology: A systematic review and meta-analysis. Obstet Gynecol 111:167-177, 2008
17. Siebers AG, Klinkhamer PJ, Grefte JM, et al: Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: A randomized controlled trial. JAMA 302:1757-1764, 2009
18. Solomon D, Davey D, Kurman R, et al: The 2001 Bethesda System: Terminology for reporting results of cervical cytology. JAMA 287:2114-2119, 2002
19. Liaw KL, Hildesheim A, Burk RD, et al: A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 183:8-15, 2001
20. Liaw KL, Glass AG, Manos MM, et al: Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 91:954-960, 1999
21. Castle PE, Lorincz AT, Scott DR, et al: Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer. J Clin Microbiol 41:4022-4030, 2003
22. Smith JS, Lindsay L, Hoots B, et al: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer 121:621-632, 2007
23. de Sanjose S, Quint WG, Alemany L, et al: Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol 11:1048-1056, 2010
24. Stoler MH, Wright TC Jr, Sharma A, et al: High-risk human papillomavirus testing in women with ASC-US cytology: Results from the ATHENA HPV study. Am J Clin Pathol 135:468-475, 2011
25. Einstein MH, Martens MG, Garcia FA, et al: Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology. Gynecol Oncol 118:116-122, 2010
26. Bouvard V, Baan R, Straif K, et al: A review of human carcinogens: Part B - Biological agents. Lancet Oncol 10:321-322, 2009
27. Saslow D, Solomon D, Lawson HW, et al: American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 62:147-172, 2012
28. Cuzick J, Clavel C, Petry KU, et al: Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119:1095-1101, 2006
29. Ronco G, Giorgi-Rossi P, Carozzi F, et al: Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 100:492-501, 2008
30. Sankaranarayanan R, Nene BM, Shastri SS, et al: HPV screening for cervical cancer in rural India. N Engl J Med 360:1385-1394, 2009
31. Kjaer SK, Frederiksen K, Munk C, et al: Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: Role of persistence. J Natl Cancer Inst 102:1478-1488, 2010
32. Wright TC Jr, Schiffman M, Solomon D, et al: Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 103:304-309, 2004
33. Wright TC Jr, Massad LS, Dunton CJ, et al: 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 11:201-222, 2007
34. Castle PE, Fetterman BJ, Thomas Cox J, et al: The age-specific relationships of abnormal cytology and HPV DNA results with the risk of cervical precancer and cancer. Obstet Gynecol 116:76-84, 2010
35. Castle PE, Schiffman M, Wheeler CM, et al: Human papillomavirus genotypes in cervical intra-epithelial neoplasia grade 3. Cancer Epidemiol Biomarkers Prev 19:1675-1681, 2010
36. Wheeler CM, Hunt WC, Joste NE, et al: Human papillomavirus genotype distributions: Implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 101:475-487, 2009
37. Castellsagué X, Díaz M, de Sanjosé S, et al: Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: Implications for screening and prevention. J Natl Cancer Inst 98:303-315, 2006
38. Reimers LL, Anderson WF, Rosenberg PS, et al: Etiologic heterogeneity for cervical carcinoma by histopathologic type, using comparative age-periodcohort models. Cancer Epidemiol Biomarkers Prev 18:792-800, 2009
39. Bray F, Carstensen B, Møller H, et al: Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 14:2191-2199, 2005
40. Sasieni P, Castanon A, Cuzick J: Screening and adenocarcinoma of the cervix. Int J Cancer 125:525-529, 2009
41. Katki HA, Kinney WK, Fetterman B, et al: Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: A population-based study in routine clinical practice. Lancet Oncol 12:663-672, 2011
42. Wang SS, Sherman ME, Hildesheim A, et al: Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 100:1035-1044, 2004